Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31014743 | 0.98 | NPC1 (0.40) | NPC1RAB9AKMT2AHSD11B1KDM4E | |
| SCHEMBL31706833 | 0.85 | HTR2C (0.51) | KMT2AKDM4EPIM2MEN1ALDH1A1 | |
| SCHEMBL31705338 | 0.85 | PIK3CA (0.44) | NPC1RAB9AKMT2AKDM4ENPSR1 | |
| SCHEMBL31705963 | 0.85 | HTR2C (0.51) | KMT2AKDM4EPIM2MEN1ALDH1A1 | |
| SCHEMBL24993524 | 0.85 | PIK3CA (0.44) | NPC1RAB9AKMT2AKDM4ENPSR1 | |
| SCHEMBL4566530 | 0.85 | HTR2C (0.51) | KMT2AKDM4EPIM2MEN1ALDH1A1 | |
| SCHEMBL24993520 | 0.84 | SCN10A (0.42) | — | |
| SCHEMBL24993522 | 0.83 | DPP4 (0.40) | KDM4EHRH3 | |
| SCHEMBL24993525 | 0.82 | DRD2 (0.40) | KDM4EHRH3ALDH1A1 | |
| SCHEMBL10367486 | 0.81 | PIM2 (0.45) | NPC1RAB9AKMT2AHSD11B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023010191-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | EUROFARMA LABORATÓRIOS S.A. (BR) | 2023-02-09 | — | — | WO | disclosed |
| WO-2022076622-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |